Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
View Patent ↗A method for lowering elevated uric acid levels in patients is disclosed and consists of administering to the patients an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg.
1. A method for lowering elevated uric acid levels in a patient comprising administering to said patient an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg of uricase, the uricase consisting of the amino acid sequence of SEQ ID NO:8, wherein said administration takes place from about every 2 to 4 weeks, wherein a plasma uricase activity level is undetectable in the patient prior to a first intravenous injection of PEG-uricase, and wherein the plasma uricase activity level is detectable about 21 days after the intravenous injection.
2. The method of claim 1 , wherein said dosage is between 4 and 8 mg of uricase.
3. The method of claim 1 , wherein said dosage is between 8 and 12 mg of uricase.
4. The method of claim 1 , wherein said dosage is about 4 mg of uricase.
5. The method of claim 1 , wherein said patient is suffering from gout.
6. The method of claim 5 , wherein said gout is refractory.
7. The method of claim 5 , wherein said gout is chronic or tophaceous.
8. The method of claim 1 , wherein said patient has a plasma level of uric acid (pUAc) of more than about 6 mg/dL before said administration.
9. The method of claim 1 , wherein the plasma uricase activity level is detectable in the patient from about 26 mU/mL to about 6.5 mU/mL about 21 days after the intravenous injection.
10. A method for lowering elevated uric acid levels in a patient comprising administering to said patient an intravenous injection of PEG-uricase having a dosage from about 0.5 to about 12 mg of uricase, the uricase consisting of the amino acid sequence of SEQ ID NO:8, wherein said administration takes place from about every 2 to 4 weeks, and wherein a plasma uricase activity level is undetectable in the patient prior to a first intravenous injection of PEG-uricase, and wherein the plasma uricase activity level is detectable about 21 days after the intravenous injection.
11. The method of claim 10 , wherein said dosage is between 4 and 8 mg of uricase.
12. The method of claim 10 , wherein said dosage is between 8 and 12 mg of uricase.
13. The method of claim 10 , wherein said dosage is about 4 mg of uricase.
14. The method of claim 10 , wherein said patient is suffering from gout.
15. The method of claim 14 , wherein said gout is refractory.
16. The method of claim 14 , wherein said gout is chronic or tophaceous.
17. The method of claim 10 , wherein said patient has a plasma level of uric acid (pUAc) of more than about 6 mg/dL before said administration.
18. The method of claim 10 , wherein the plasma uricase activity level is detectable in the patient from about 26 mU/mL to about 6.5 mU/mL about 21 days after the intravenous injection.